Scheid, C., Roellig, C., Weisel, K., Salwender, H-J, Gramatzki, M., Edmaier-Schroeger, K., Sy, O. and Goldschmidt, H. (2018). Durable progression-free survival benefit in early responders to elotuzumab plus lenalidomide and dexamethasone (ELd): analysis of ELOQUENT-2 4-year data in relapsed/refractory (RR) multiple myeloma (MM). Oncol. Res. Treat., 41. S. 189 - 190. BASEL: KARGER. ISSN 2296-5262

Full text not available from this repository.

Item Type: Journal Article
Creators:
CreatorsEmailORCIDORCID Put Code
Scheid, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Roellig, C.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Weisel, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Salwender, H-JUNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Gramatzki, M.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Edmaier-Schroeger, K.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Sy, O.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
Goldschmidt, H.UNSPECIFIEDUNSPECIFIEDUNSPECIFIED
URN: urn:nbn:de:hbz:38-201575
Journal or Publication Title: Oncol. Res. Treat.
Volume: 41
Page Range: S. 189 - 190
Date: 2018
Publisher: KARGER
Place of Publication: BASEL
ISSN: 2296-5262
Language: English
Faculty: Unspecified
Divisions: Unspecified
Subjects: no entry
Uncontrolled Keywords:
KeywordsLanguage
OncologyMultiple languages
Refereed: Yes
URI: http://kups.ub.uni-koeln.de/id/eprint/20157

Downloads

Downloads per month over past year

Export

Actions (login required)

View Item View Item